Metabolism & incretins
Semaglutide
Also known as: GLP-1-RA, Ozempic, Wegovy (Markenname)
A long-acting GLP-1 receptor agonist and one of the most discussed peptides worldwide; approved in the EU as Ozempic, Rybelsus and Wegovy.
Structure
- Molecular formula
- C₁₈₇H₂₉₁N₄₅O₅₉S
- Molecular weight
- 4,113 Da
- Amino acids
- 31
Mechanism of action
Semaglutide binds the GLP-1 receptor with high affinity. It stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and activates satiety centres in the hypothalamus.
Studies
More in Metabolism & incretins
More detail (research areas, comparisons, FAQ): German lexicon entry.